<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="327">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156892</url>
  </required_header>
  <id_info>
    <org_study_id>TICTOC</org_study_id>
    <nct_id>NCT05156892</nct_id>
  </id_info>
  <brief_title>Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer</brief_title>
  <acronym>TICTOC</acronym>
  <official_title>A Phase I/II Trial Investigating the Tolerability, Toxicity and Efficacy of Tamoxifen and SUBA-Itraconazole in Patients With Platinum Resistant Recurrent Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthony Joshua, FRACP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Prince Alfred Hospital, Sydney, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Concord Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prince of Wales Hospital, Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St Vincent's Hospital, Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St Vincent's Hospital, Sydney</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's purpose is to understand the effects of a new treatment (suba-itraconazole and&#xD;
      tamoxifen) in epithelial ovarian cancer.&#xD;
&#xD;
      Who is it for? Patients may be eligible to join this study with ovarian cancer resistant to&#xD;
      platinum-based chemotherapy agents&#xD;
&#xD;
      Study Details:&#xD;
&#xD;
      Participants will receive different doses of tamoxifen and suba-itraconazole to determine the&#xD;
      optimal combination dose.&#xD;
&#xD;
      Participants will be seen by the investigators once a week for the first 3 weeks and then&#xD;
      once every 4 weeks. Participant will be reviewed by a clinician and undergo regular blood&#xD;
      tests, cardiac monitoring and imaging assessments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 1/2 study of Suba-itraconazole and Tamoxifen in platinum resistant ovarian carcinoma&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose Escalation (3+3) design with Dose Expansion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase 2 dose of Tamoxifen in combination with Suba-itraconazole</measure>
    <time_frame>1 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine overall response rate as determined by RECIST V1.1 and GCIG CA125 response criteria</measure>
    <time_frame>2 years</time_frame>
    <description>ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the duration of response</measure>
    <time_frame>2 years</time_frame>
    <description>DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events via CTCAE v5.0</measure>
    <time_frame>2 years</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of tamoxifen and derivatives</measure>
    <time_frame>2 years</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of tamoxifen and derivatives</measure>
    <time_frame>2 years</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue concentration of tamoxifen and derivatives</measure>
    <time_frame>2 years</time_frame>
    <description>mg/g</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of itraconazole</measure>
    <time_frame>2 years</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of itraconazole</measure>
    <time_frame>2 years</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue concentration of itraconazole</measure>
    <time_frame>2 years</time_frame>
    <description>mg/g</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Dose-escalation/ expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SUBA-itraconazole (oral 150mg twice daily) and escalating dose of Tamoxifen (oral once daily) then expansion cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUBA-itraconazole</intervention_name>
    <description>150 mg BD</description>
    <arm_group_label>Dose-escalation/ expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>Dose Escalation:&#xD;
Cohort 1: 20 mg OD Cohort 2: 40 mg OD Cohort 3: 60 mg OD&#xD;
Dose-Expansion: Recommended dose from dose-escalation phase of study</description>
    <arm_group_label>Dose-escalation/ expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological or cytological-based diagnosis of high grade and low grade epithelial&#xD;
             ovarian cancer. Patients with clear cell ovarian cancers are not eligible to&#xD;
             participate in this study due to higher risk of thromboemboli which could be increased&#xD;
             by Tamoxifen.&#xD;
&#xD;
          2. Platinum resistant ovarian cancer with no more than 4 lines of previous systemic&#xD;
             therapy (re-treatment with a previous regimen is only counted as 1 line of therapy).&#xD;
&#xD;
          3. Age &gt; 18 years.&#xD;
&#xD;
          4. Patient must be willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests and other study procedures&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group Performance Status of 0 or 1&#xD;
&#xD;
          6. Adequate hematologic and organ function within 14 days before the first study&#xD;
             treatment on Day 1 of Cycle 1, defined by the following:&#xD;
&#xD;
               -  Neutrophils (absolute neutrophil count ANC &gt;1.5X10^9/L,)&#xD;
&#xD;
               -  Hemoglobin &gt;9 g/dL&#xD;
&#xD;
               -  Platelet count &gt;100,000/L&#xD;
&#xD;
               -  Serum albumin &gt;3 g/dL&#xD;
&#xD;
               -  Total bilirubin 1.5 ≤the upper limit of normal (ULN) and AST and ALT ≤2.5 XULN,&#xD;
                  with the following exception:&#xD;
&#xD;
                    -  Patients with known Gilbert syndrome who have serum bilirubin ≤3XULN may be&#xD;
                       enrolled.&#xD;
&#xD;
                    -  Patients with documented liver metastasis may have AST and ALT ≤5XULN&#xD;
&#xD;
               -  PTT (or aPTT) and INR ≤1.5XULN (except for patients receiving anticoagulation&#xD;
                  therapy)&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5XULN or creatinine clearance &gt;50 mL/min based on&#xD;
                  Cockcroft-Gault glomerular filtration rate estimation: (140 - age) X(weight in&#xD;
                  kg) X0.85 (if female) 72 X(serum creatinine in mg/dL)&#xD;
&#xD;
          7. Life expectancy of at least 3 months&#xD;
&#xD;
          8. Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1.&#xD;
             Patients without any measurable disease may be enrolled on a case-by-case basis in&#xD;
             discussion with study principle investigator&#xD;
&#xD;
          9. At least 4 weeks washout period from previous line of treatment (including hormonal&#xD;
             treatment) , 2 weeks from radiotherapy&#xD;
&#xD;
         10. Ability to swallow and retain oral medications (without crushing, dissolving or&#xD;
             chewing tablets)&#xD;
&#xD;
         11. Willing and able to comply with all study requirements, including treatment (e.g. able&#xD;
             to swallow tablets), timing and/or nature of required assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with any other prior malignancy from which the patient has been disease free&#xD;
             for less than 3 years, with the exception of adequately treated and cured basal or&#xD;
             squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of any site&#xD;
             or any other cancer as approved by study principle investigator&#xD;
&#xD;
          2. Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, symptomatic or asymptomatic congestive heart failure, unstable angina&#xD;
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
&#xD;
          3. History of or current evidence of HIV infection, Viral hepatitis (e.g., positive for&#xD;
             hepatitis B surface antigen [HBsAg] or hepatitis C virus [HCV] antibody at screening)&#xD;
&#xD;
          4. Patients with symptomatic central nervous system (CNS) metastasis and/or carcinomatous&#xD;
             meningitis. Patients with treated CNS metastases are eligible for this study if not&#xD;
             receiving corticosteroids and/or anticonvulsants for at least 7 days prior to first&#xD;
             dose of study treatment, and the disease is asymptomatic and radiographically stable&#xD;
             for at least 2 weeks after completion of CNS-directed therapy. Patients with untreated&#xD;
             stable or asymptomatic brain metastases may be enrolled on a case-by-case basis in&#xD;
             discussion with study principal investigator.&#xD;
&#xD;
          5. Patients with existing or past history of deep venous thromboembolism are excluded,&#xD;
             unless stable on anticoagulation.&#xD;
&#xD;
          6. Patients with Khorana score of greater than or equal to 3 (see&#xD;
             https://www.mdcalc.com/khorana-risk-score-venousthromboembolism- cancer-patients)&#xD;
&#xD;
          7. Known hypersensitivity or contraindication to any component of the study treatment.&#xD;
&#xD;
          8. Inability to comply with study and follow-up procedures.&#xD;
&#xD;
          9. Patients who have not recovered (≤ grade 2) from adverse events related to previous&#xD;
             treatments, unless approved by study principle investigator&#xD;
&#xD;
         10. Patients unable to swallow orally administered medications and patients with&#xD;
             gastrointestinal impairment that could affect the ability to take or absorption of&#xD;
             oral medications including sub-acute or complete bowel obstruction.&#xD;
&#xD;
         11. Participants with uncontrolled intercurrent illness&#xD;
&#xD;
         12. Participants not recovered from all toxicities related to prior anticancer therapies&#xD;
             to CTCAE grade&lt;1 apart from alopecia&#xD;
&#xD;
         13. Patients with psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>It is a female only study population as it is investigating Ovarian Cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Joshua, FRACP, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Vincent's Hospital, Sydney</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony Joshua, FRACP, MBBS, PhD</last_name>
    <phone>+61 293555655</phone>
    <email>Anthony.Joshua@svha.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Kent</last_name>
    <phone>+61 293555611</phone>
    <email>SVHS.CancerResearch@svha.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kinghorn Cancer Centre, St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>December 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 13, 2021</last_update_submitted>
  <last_update_submitted_qc>December 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Vincent's Hospital-Manhattan</investigator_affiliation>
    <investigator_full_name>Anthony Joshua, FRACP</investigator_full_name>
    <investigator_title>Head of Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>SUBA-Itraconazole</keyword>
  <keyword>Platinum resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No Plan to share participant data with individuals outside this trial</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

